Background Nutritional ergogenic aids are foods or nutrients that can improve physical performance. Among these foods with ergogenic properties, caffeine has shown that it can increase the fat catabolism, strength, and improve the cognition and time reaction of an athlete, therefore, it is hoped that it can improve the performance of judokas. This study through a double-blind crossover (supplement X placebo) protocol, investigated the effects caffeine supplementation (single capsule containing 5 mg/kg body mass intake 60 min before the session) on biochemical, anthropometrical, physical, subjective and hemodynamic variables measured before, during and after two typical judo trainingcxs sessions (120-min: 40-min of gymnastics; 40-min of specific technics and; 40-min of judo combat). Methods 8 high-level athletes (21.4 ± 2.0 years; 83.6 ± 15.2 kg; 1.8 ± 0.1 m; 17.9 ± 7.0 Fat%) were evaluated before and after each training for body mass, hydration, upper and lower limb power, performance in the special judo fitness test (SJFT), free fatty acids (FFA) in plasma, uric acid, glucose, lactate, heart rate, and pain. In addition, heart rate, FFA in plasma, uric acid, glucose, lactate, rating of perceived exertion and pain were assessed during the training. Results At 120 min, supplementation resulted in a higher concentration of plasma FFA (1.5 ± 0.5 vs. 1.0 ± 0.3 mmol/L; p = 0.047) and lactate (4.9 ± 1.8 vs. 3.0 ± 1.2 mmol/L; p = 0.047), and a lower concentration of uric acid (5.4 ± 0.9 vs. 7.0 ± 1.5 mg/dL; p = 0.04). Supplementation also resulted in performance maintenance (fatigue index) in the SJFT (Δ0.3 ± 2.0 vs Δ1.7 ± 2.5, for caffeine and placebo respectively, p = 0.046). No adverse effects were observed. Conclusion Based on the applied dose, intake time, and sample of this study, we can conclude that caffeine produces an ergogenic biochemical effect, and improves performance in judo athletes.

This brief research report showed technical-tactical behaviors of male and female judo cadets during combats, comparing the frequency and time of judo combat actions, techniques and penalties. The data was composed for 3,240 sequential technical-tactical behavior analysis from 108 female and 300 male cadet combats recorded of public judo championships. Combat, standing combat moments, approach action, gripping action, attack, groundwork actions and pause moment were observed and determinant technical-tactical behaviors (frequencies of actions, penalties and type of attacks) analysis were done with FRAMI software, followed by Mann-Whitney and Student's t-test, p ≤ 0.05. Our main results indicated that male cadets with 58.66s ± 50.26s demonstrated longer gripping action than female with 38.44s ± 30.44s, as standing combat (tachi-waza) had differences between male with 96.8s ± 72s and female athletes with 75.85s ± 56.97s. Moreover, male cadets had higher sacrifice techniques (sutemi-waza) actions than female athletes. This information could be used to a best performance associated with "psyching-up" as much as it could be used on physical training and technical-tactical ability of female and male cadets.

Recent evidence suggests changes in circulating microRNA levels may be promising biomarkers for the clinical diagnosis of Alzheimer disease (AD). We hypothesized that whole-blood microRNAs may be useful to identify individuals with established AD. For this purpose, a sample of community-dwelling women (≥55 years old) carrying the ApoE ∊4 allele were clinically evaluated using the American Psychiatric Association/ Diagnostic and Statistical Manual of Mental Disorders, Fourth edition and the Alzheimer Disease Assessment Scale–Cognitive Subscale criteria to diagnose probable AD, and the Clinical Dementia Rating scale to stage the dementia. A set of 25 mature microRNAs was rationally selected for evaluation based on experimental evidence of interaction with genes linked to the late-onset AD neuropathology. Whole-blood concentrations were determined by quantitative real-time polymerase chain reaction. Compared to patients without dementia, a median 3-fold decrease in miR-9 levels was found among patients with AD ( P = .001). Our findings support blood-borne miR-9 as a candidate biomarker for probable AD, embodied by evidence from the literature of its implication in amyloidogenesis.

No abstract